luvesilocin

Luvesilocin is a synthetic tryptamine prodrug designed for rapid-acting antidepressant effects with a shorter psychoactive duration than traditional psychedelics. Developed by Reunion Neuroscience, it is a prodrug of 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT). The molecule acts as a non-selective serotonin receptor agonist, primarily targeting the 5-HT2A receptor to induce neuroplasticity and therapeutic psychological effects. It is administered via subcutaneous injection and is currently being evaluated in Phase 2 clinical trials for postpartum depression (PPD), where it has received FDA Breakthrough Therapy Designation. Its design aims for a clinical experience lasting approximately 3.6 hours, facilitating easier integration into standard clinical practice compared to psilocybin.

Other names

4-glutaryloxy-N,N-diisopropyltryptamine4-HO-DiPT O-glutarate4-GO-DiPT